Parkinson Disease clinical trials

The registry lists 4,576 studies for Parkinson Disease across more than 10 countries. 1,087 are recruiting or about to start. 4,103 of them are mainly about Parkinson Disease (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

ClinicalTrials.gov finds 5,071 studies for Parkinson Disease. How that becomes 4,569 here

This page counts the studies the registry files under Parkinson Disease, and those it files under no condition that list Parkinson Diseasethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

5,071Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−48List Parkinson Disease as a condition, but the registry did not file them under itMost often written as “Parkinson Disease Dementia” (10), “Parkinson's Disease Dementia” (6), and “Advanced Parkinson's Disease” (5). The registry filed them under other conditions only, most often Lewy Body Disease (21) and Alzheimer Disease (12).
−454Match it another way130 name it in the title, 8 in a keyword, and 316 by a synonym or other text the search reads.
4,569The count on this page78 of them list Parkinson Disease in their own words; the registry filed them under no condition.

Get an email when these change. Save the Parkinson Disease studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 2,414
Recruiting: 749
Status unknown: 513
Terminated: 254
Not yet recruiting: 253
Active, not recruiting: 178

Phase

Phase 2: 620
Phase 1: 440
Phase 3: 304
Phase 4: 179
Early Phase 1: 59

Where

United States: 1,649
France: 428
Italy: 347
China: 278
Germany: 262
Canada: 253

Who runs them

National Institute of Neurological Disorders and Stroke (NINDS) (63) · Bial - Portela C S.A. (57) · VA Office of Research and Development (43) · Boehringer Ingelheim (42) · University of Florida (41) · Oregon Health and Science University (36) · AbbVie (35) · Radboud University Medical Center (34)

What is being tested here

Drugs under test in Parkinson Disease studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Levodopa	3	9	48
Lidocaine	3	0	3
Prasinezumab	2	1	6
Ambroxol	2	2	6
IPX203	2	2	5
Terazosin	2	1	5
Ketamine	2	0	4
Lu AF28996	2	0	4
Metformin	2	2	3
Psilocybin	2	0	3

Drug classes tested here Local anesthetics 3 open · Dopamine agonists 2 open · Cholinesterase inhibitors 2 open · Serotonin receptor agonists 2 open · Antipsychotics 2 open

Coming up

25phase 3 studies under way

385studies finish main data collection within a year6 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Nov 2026Vinpocetine in Patients With Parkinsonian Disease · Phase 3 · Tanta University
Nov 2026Metformin in Parkinson Disease · Phase 3 · Tanta University
Dec 2026Fexofenadine as Adjuvant Therapy in Parkinson Disease · Phase 3 · Tanta University
Jul 2027Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach · Phase 3 · Radboud University Medical Center
Aug 2027A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease · Phase 3 · Biohaven Therapeutics Ltd.
Oct 2027VG081821AC Tablets for Early to Mid-stage Parkinson's Disease · Phase 3 · Zhejiang Vimgreen Pharmaceuticals, Ltd.
Nov 2026Cerebellar Transcranial Direct Current Stimulation in Parkinson's Disease · Université Libre de Bruxelles
Nov 2026Synthetic Vasomotion for Glymphatic Enhancement · Florida Institute for Human and Machine Cognition
Nov 2026Pilot Study of Robotic Spinal Mobilization in Parkinson's Disease · Pacla Medical Limited
Nov 2026Effects of the Stimulation Site of tsMS With TMS on Functional Mobility in Individuals With Parkinson's Disease · Universidade Federal de Pernambuco

Who these studies take

Of the 749 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger. 64 (9%) take children under 18. 2 (<1%) are for women only and 3 (<1%) for men only; 189 (25%) take healthy volunteers.

Recruiting studies that take each age, of 749
Age	Women	Men
10	61 (8%)	61 (8%)
18	364 (49%)	363 (48%)
30	459 (61%)	457 (61%)
40	586 (78%)	584 (78%)
50	729 (97%)	727 (97%)
65	737 (98%)	739 (99%)
75	689 (92%)	688 (92%)
85	469 (63%)	468 (62%)

Across all 4,576 studies, recruiting or not: 18% stop at 75 or younger and 4% at 65; 9% take children; <1% are for women only and 1% for men only; 22% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Parkinson Disease studies take

Of 204 phase 1 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	19 mo5–40 · 204 studies	9 mo3–24 · 127 studies	37 mo20–68 · 77 studies
Phase 1/2	25 mo12–53 · 55 studies	—	—
Phase 2	28 mo16–44 · 201 studies	19 mo13–33 · 96 studies	35 mo24–59 · 105 studies
Phase 2/3	22 mo18–50 · 22 studies	—	—
Phase 3	35 mo22–56 · 67 studies	31 mo20–54 · 39 studies	—
Phase 4	28 mo19–65 · 56 studies	—	41 mo21–75 · 41 studies
Interventional, no phase	25 mo12–44 · 1,369 studies	27 mo17–43 · 76 studies	24 mo11–44 · 1,293 studies
Observational	47 mo22–114 · 439 studies	37 mo19–64 · 60 studies	48 mo22–133 · 379 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out